<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03671161</url>
  </required_header>
  <id_info>
    <org_study_id>CIC1421-18-15</org_study_id>
    <nct_id>NCT03671161</nct_id>
  </id_info>
  <brief_title>Flash Glucose Measure System and Continuous Subcutaneous Insulin Infusion Therapy in Poorly Controlled Diabetes Type 1 Patients</brief_title>
  <acronym>FREESTYLE</acronym>
  <official_title>Combination of Flash Glucose Measure System and Continuous Subcutaneous Insulin Infusion Therapy in Patients With Type 1 Diabetes and Poor Glycemic Control Related to Very Few Self-blood Glucose Measurements</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Pitie-Salpetriere</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with diabetes type 1 with poor glycemic control will be switched to insulin pump and
      FGM system (Flash Glucose Monitoring) during 6 months, correlated to the hypothesis that they
      could benefit from this intervention by being reengaged in diabetes self-management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-controlled proof of concept prospective pilot study in adults with type 1
      diabetes, HbA1c &gt;9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less
      than 2 SMBG /day. Patients will be switched to insulin pump and started a FGM system (Free
      Style Libre®) during 6 months, hoping this intervention can reengage patients in
      self-management, reduce HbA1c without increasing the risk of ketoacidocetosis (DKA) and
      severe hypoglycemia (SH), and keep the DTSQ (Diabetes Treatment Satisfaction Questionnaire)
      and HFS (Hypoglycemia Fear Scale) at good levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">July 1, 2017</completion_date>
  <primary_completion_date type="Actual">July 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>19 patients with type 1 diabetes, HbA1c &gt;9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c ≥1%</measure>
    <time_frame>6 months</time_frame>
    <description>Blood samples at baseline and 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of severe hypoglycemia episodes</measure>
    <time_frame>6 months</time_frame>
    <description>Number of severe hypoglycemia episodes, evaluated by flash glucose monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of ketoacidosis episodes</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any positive change in DTSQ scale (ΔDTSQM6-DTSQM0&gt;0) (Diabetes Treatment Satisfaction Questionnaire)</measure>
    <time_frame>6 months</time_frame>
    <description>Filling questionnaires at baseline and 6 months. DTSQ (Diabetes treatment questionnaire) includes 8 items, each score from 0 to 6 with a higher score indicating better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any positive change in HFS scale (Hypoglycemia Fear Scale)</measure>
    <time_frame>6 months</time_frame>
    <description>Filling questionnaires at baseline and 6 months. HFS (Hypoglycemia fear scale) assesses participant's fear of hypoglycemia both overall and separately for behavior (10 items) and worry (17 items), both items scoring from 1 to 5, with lower score indicating better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hypoglycemia episodes</measure>
    <time_frame>6 months</time_frame>
    <description>Number of hypoglycemia episodes, evaluated by Flash glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of hypoglycemia episodes</measure>
    <time_frame>6 months</time_frame>
    <description>Frequency of hypoglycemia episodes, evaluated by Flash glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of severe hypoglycemia episodes</measure>
    <time_frame>6 months</time_frame>
    <description>Frequency of severe hypoglycemia episodes, evaluated by Flash glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of ketoacidosis episodes</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any changes in Weight</measure>
    <time_frame>6 months</time_frame>
    <description>Weight measures at baseline 2 months and 6 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Glucose Metabolism Disorders (Including Diabetes Mellitus)</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Patients with poorly controlled diabetes type 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults with type 1 diabetes, HbA1c &gt;9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day swithced to Insulin Pump and flash glucose monitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Insulin Pump and flash glucose monitoring</intervention_name>
    <description>Adults with type 1 diabetes, HbA1c &gt;9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day. Patients will be switched to insulin pump and start a FGM system (Free Style Libre®) during 6 months.</description>
    <arm_group_label>Patients with poorly controlled diabetes type 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults with type 1 diabetes, aged between 18 and 55, HbA1c &gt;9% (75 mmol/mol), multi
             daily insulin injections (MDI) treatment, maximum 2 SMBG /day

        Exclusion Criteria:

          -  diabetes with less than 1 year duration, severe active retinopathy requiring laser
             therapy, severe psychiatric illness, pregnancy, inability to communicate in French,
             concomitant severe active disease, patients already using a FGM or a CGM
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Halbron M, Bourron O, Andreelli F, Ciangura C, Jacqueminet S, Popelier M, Bosquet F, Rouanet S, Amouyal C, Hartemann A. Insulin Pump Combined with Flash Glucose Monitoring: A Therapeutic Option to Improve Glycemic Control in Severely Nonadherent Patients with Type 1 Diabetes. Diabetes Technol Ther. 2019 Jul;21(7):409-412. doi: 10.1089/dia.2019.0041.</citation>
    <PMID>31265349</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 7, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groupe Hospitalier Pitie-Salpetriere</investigator_affiliation>
    <investigator_full_name>Joe Elie Salem</investigator_full_name>
    <investigator_title>Assistant director, clinical investigation center Paris Est</investigator_title>
  </responsible_party>
  <keyword>Diabetes Type 1</keyword>
  <keyword>Insulin Pump</keyword>
  <keyword>flash glucose monitoring</keyword>
  <keyword>hypoglycemia</keyword>
  <keyword>ketoacidocetosis</keyword>
  <keyword>DTSQ</keyword>
  <keyword>HFS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

